Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
March 15, 2021

LoA Update: Locus’ UTI therapy sees 2-point decrease in FDA approval shot despite positive Phase Ib, but still has 92% possibility of regulatory success

Locus Biosciences’ Escherichia coli urinary tract infection (UTI) asset LBPEC-01 had a two-point drop in its FDA likelihood of approval (LoA) as of 26 February even with positive Phase Ib data.

By Reynald Castañeda

Locus Biosciences’ Escherichia coli urinary tract infection (UTI) asset LBPEC-01 had a two-point drop in its FDA likelihood of approval (LoA) as of 26 February even with positive Phase Ib data. Although its approval prospects decreased, the therapy’s current LoA remains high at 92%, according to GlobalData analysis using a combination of machine learning and its proprietary algorithm.

LBPEC-01 is a CRISPR-Cas3-enhanced bacteriophage (crPhase) approach that targets E. coli in patients with UTI. On 24 February, the North Carolina-headquartered company reported the 36-patient Phase Ib demonstrated LBP-EC01 use can decrease levels of susceptible bacteria in patients with E. coli in the bladder, with no reported drug-related adverse events. The trial had a primary endpoint investigating safety and therapy pharmacokinetics. Locus plans to advance LBPEC-01 into Phase II exploration, as per a media release.

Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU